Jefferies analyst Michael Yee raised the firm’s price target on Moderna (MRNA) to $155 from $125 and keeps a Buy rating on the shares following a “nice” quarter that was “generally in line” with “no major surprises.” The focus now shifts to RSV approval due around May 12 and the launch and while the company won’t comment on RSV guidance, consensus is only $280M and at a fraction of GSK (GSK) and Pfizer (PFE) sales “seems low,” the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRNA:
- Moderna Reports Earnings: Did it Beat Estimate Forecasts?
- MRNA Earnings: Moderna Reports Mixed Results in Q1
- Metagenomi price target lowered to $17 from $21 at ChardanModerna
- Options Volatility and Implied Earnings Moves Today, May 02, 2024
- Moderna: 2024 expectations remain consistent with prior expectations
